Table of Content

08 June 2015, Volume 42 Issue 6 Previous Issue    Next Issue

For Selected:

Download Citations EndNote Reference Manager ProCite BibTeX RefWorks

Toggle Thumbnails

Artemether inhibits proliferation and invasion via the mediation of peroxisome proliferatoractivated receptorgamma activation pathway in Lewis lung cancer cells 2015, 42 (6):  401-406.  doi: 10.3760/cma.j.issn.1673-422X.2015.06.001 Abstract ( 445 )   PDF (1095KB) ( 1365 )   Save ObjectiveTo investigate the inhibitory effect of artemether (ARE), one of artemisinin derivatives, on the growth and invasion of Lewis lung cancer cells (LCCs) in vitro and explore the possible mechanism. MethodsEffects of ARE on proliferation of LLCs were evaluated by MTT. The invasiveness was detected by Transwell invasion assay, including control, ARE, GW9662 ［the specific inhibitor of peroxisome proliferatoractivated receptor γ (PPARγ)］ and GW9662+ARE group. The expression levels of PPARγ, NFκB p65, Caspase3 mRNA and protein in abovementioned four groups were analyzed by RTPCR and Western blotting, respectively. ResultsARE could inhibit the proliferation of LLCs in time and dosedependent manner, the IC50 value of which in 24, 48, and 72 h were 271.29, 189.08, 65.99 μg/ml, respectively. The fluorescent value of ARE group was 1 744.67, and that of control group was 6 887.00, 4 597.00 of GW+ARE group, as well as 10 012.67 of GW9662 group. It manifested the invasiveness of ARE group was the weakest, which declined significantly compared with control group (t=12.411，P=0.000). The relative quantitative expressions of PPARγ mRNA in ARE and GW9662 group were 2.276±0.534 and 0.362±0.026, respectively. Compared with control group, PPARγ mRNA level in both of ARE and GW9662 group reached statistical significance (t=4.785, P=0.001; t=2.395, P=0.044). PPARγ protein expression in ARE group，GW9662+ARE group and control group were 27 688.33±3 593.06, 21 816.00±1 644.07, 17 716.33±2 273.95, respectively, which was higher in ARE group than that in control and GW+ARE group (t=5.159, P=0.001; t=3.038, P=0.016). NFκB p65 mRNA expression in GW9662+ARE group was 0.346±0.149, which in ARE group and GW9662 group were 0.392±0.187 and 1.720±0.338, respectively. The differences of NFκB p65 mRNA expression level between ARE, and control or GW9662 group were statistically significant (t=3.592, P=0.007; t=7.851, P=0.000). While, the differences of Caspase3 mRNA and protein expression levels among the four groups were not statistically significant (F=1.181, P=0.376; F=0.647, P＞0.05). ConclusionARE may restrain NFκB through upregulating PPARγ to inhibit the proliferation and invasive potential of LLC in vitro, which suggests that PPARγ may be a novel therapeutic target for lung cancer. Related Articles | Metrics

Characteristics and clinical values of SPECT/CT whole body bone scanning in detecting bone metastases in patients with lung adenocarcinoma or squamous cell carcinoma 2015, 42 (6):  407-409.  doi: 10.3760/cma.j.issn.1673-422X.2015.06.002 Abstract ( 1234 )   PDF (1056KB) ( 1527 )   Save ObjectiveTo investigate the clinical values and characteristics of whole body bone imaging (SPECT/CT) in detecting bone metastases in the preoperative patients with lung adenocarcinoma or squamous cell carcinoma for staging and determining the best treatment plan. MethodsEightytwo preoperative patients with primary pulmonary adenocarcinoma or squamous cell carcinoma performed 99TcmMDP SPECT/CT wholebody bone imaging. One week before surgery, parts of positive lesions performed MRI scan. The difference of the incidence of bone metastasis was analysed by χ2 test.ResultsIn all 82 patients with lung cancer, there were 38 adenocarcinomas and 44 squamous cell carcinomas. Bone metastases were detected in 38 cases, the incidence rate was 46.3%. Of which, among lung adenocarcinoma, the incidence rate was 57.9% (22/38), and the incidence rate was 36.4% (16/44) in lung squamous cell carcinoma, and the difference was statistically significant (χ2=12.66, P=0.027). The most common area was bilateral ribs, followed by vertebra, pelvis, bones of the extremities and skull. ConclusionLung adenocarcinoma compared with squamous cell carcinoma is prone to bone metastases, and bone metastases are more common in bilateral ribs. It has important value that whole body bone imaging in screening for bone metastases of preoperative patients with lung cancer for staging and making the treatment plan. References | Related Articles | Metrics

Effect analysis of prophylactic anticoagulation in the patients with nonsmall cell lung cancer Wu Tieying, Li Gailan, Chen Lin, Han Xiaolong 2015, 42 (6):  410-413.  doi: 10.3760/cma.j.issn.1673-422X.2015.06.003 Abstract ( 436 )   PDF (723KB) ( 1463 )   Save ObjectiveTo evaluate the effect of anticoagulant therapy in the patients with nonsmall cell lung cancer (NSCLC). MethodsOne hundred and fiftynine patients with NSCLC without venous thromboembolism (VTE) were divided into anticoagulant therapy group (81 cases) and control group (78 cases) by random number table method. The 81 cases in anticoagulant therapy group were treated with antitumor therapy and anticoagulant therapy, using low molecular heparin calcium 5 000 U subcutaneous injected for 1030 days, once every 12 hours. The 78 cases in control group were merely treated with antitumor therapy. ResultsAfter treated with anticoagulation therapy, patients in anticoagulant therapy group had prolonged prothrombin time ［(13.56±4.30)s vs (15.16±2.12)s; t=3.195, P=0.001］, active partial thromboplastin time ［(28.24±5.28)s vs (30.26±3.28)s; t=2.712, P=0.007)］, and a lower FIB ［(3.85±0.75)g/l vs (4.25±2.65)g/l; t=2.971, P=0.003］ compared with the patients in control group. The incidence of thrombosis rates of the two groups were 2.47% and 16.67% respectively, with statistical significance (χ2=9.901, P=0.002). Both the 1, 2 years overall survival rates of patients in anticoagulant therapy group were longer than those in control group, with statistical significances (χ2=5.496, P=0.026; χ2=4.540, P=0.046), while the 1, 2 years progressionfree survival rates of patients in the two groups were no statistical significances (χ2=2.034, P=0.182; χ2=0.091, P=0.395). Adverse reactions such as hemorrhage (4.94% vs 6.41%), thrombocytopenia (9.88% vs 8.98%), skin necrosis incidence (3.70% vs 1.28%) in the anticoagulant therapy group and control group were no statistical significances (χ2=0.516, P=0.685; χ2=0.008, P=1.000; χ2=0.847, P=0.632).ConclusionFor patients with NSCLC, prophylactic anticoagulant therapy can improve coagulation status, reduce the incidence of thrombosis, prolong OS, and no obvious adverse reactions. References | Related Articles | Metrics

Combined detection of serum DKK1 and P53 autoantibodies for the diagnostic value of esophageal squamous cell carcinoma Peng Yuhui, Chen Jianliang, Weng Xuefen, Fang Yusen, Xu Yiwei 2015, 42 (6):  414-418.  doi: 10.3760/cma.j.issn.1673-422X.2015.06.004 Abstract ( 594 )   PDF (1136KB) ( 1285 )   Save Objective To evaluate the diagnostic value of the combination of serum DKK1(Dickkopf1) and P53 autoantibodies in patients with esophageal squamous cell carcinoma (ESCC). Methods Serum levels of DKK1 and P53 autoantibodies were measured by enzymelinked immunosorbent assay (ELISA) for the 126 patients with ESCC and 60 normal controls. Receiver operating characteristics (ROC) was used to calculate the diagnostic efficiency. Results The serum levels of DKK1 and P53 autoantibodies were significantly higher in ESCC than those in normal controls ［(673.09±343.82)pg/ml vs (362.05±148.07)pg/ml, Z=6.158, P＜0.000 1; (0.398±0.546) vs (0.069±0.050), Z=3.832, P＜0.000 1］. ROC curves showed the optimum diagnostic cutoff for serum DKK1 was 588.77 pg/ml, with an area under curve (AUC) of 0.780 (95%CI: 0.715～0.844, 61.9% sensitivity, 95.0% specificity). Measurement of P53 autoantibodies demonstrated an AUC of 0.674 (95%CI: 0.598～0.750, 45.3% sensitivity, 95.0% specificity). The combination of DKK1 and P53 autoantibodies yielded an AUC of 0.843 (95%CI: 0.788～0.897, 73.8% sensitivity, 95.0% specificity). In early stage ESCC, combined detection of DKK1 and P53 autoantibodies improved the diagnostic power, with an AUC of 0.903 (95%CI: 0.845～0.961, 81.0% sensitivity, 95.0% specificity). Conclusion Serum DKK1 and P53 autoantibodies can be used as potential diagnostic biomarkers for the ESCC. Combined detection of them might aid the early diagnosis of ESCC. References | Related Articles | Metrics

Analysis of surgical treatment effects for 240 cases with early esophageal carcinoma 2015, 42 (6):  419-421.  doi: 10.3760/cma.j.issn.1673-422X.2015.06.005 Abstract ( 487 )   PDF (711KB) ( 1456 )   Save Objective  To study the effects of radical surgical treatment for early esophageal cancer, and to investigate the prevention and cure of their complications, cancer recurrence and metastasis. Methods Treatments of 240 patients with early esophageal cancer of Chinese PLA General Hospital from January 2005 to January 2009 were retrospectively analyzed. The patients were treated by left thoracotomy, thoracic or cervical mechanical anastomosis surgical methods of treatment. Their postoperative adverse reactions, complications and 1-, 3-, 5-year survival rates were observed and analyzed. Results The surgical resection rate was 100.00%. Complications included postoperative pulmonary infection (12 patients, 5.00%), cardiac arrhythmias (1 patient, 0.42%), delayed gastric emptying (2 patients, 0.83%), pleural hemorrhage (1 patient, 0.42%), recurrent laryngeal nerve injury (2 patients, 0.83%) and anastomotic fistula (1 patient, 0.42%). Oneyear, 3-year and 5-year survival rates after surgery were 100.00% (240/240), 97.9% (235/240) and 95.8% (230/240) respectively. The main causes of postoperative death were tumor recurrence and metastasis. Conclusion Timely surgery for early esophageal cancer can bring in good effect and longterm outcome, with little complication, which can obtain a good forward curative effect. References | Related Articles | Metrics

Application of two different gastrectomy methods in proximal gastric cancer Ouyang Jie, Li Hong, Chen Siyuan, Wang Libin, Li Aihui, Liu Ming, Yu Weixuan 2015, 42 (6):  422-425.  doi: 10.3760/cma.j.issn.1673-422X.2015.06.006 Abstract ( 494 )   PDF (804KB) ( 1219 )   Save Objective To evaluate the impacts of the two different gastrectomy methods on the quality of life, complication and prognosis in proximal gastric cancer. Methods One hundred and two cases of proximal gastric cancer in Tung Wah Hospital were collected for retrospective analysis. They were divided into proximal gastrectomy/gastroesophagostomy (PG) group (n=50) and total gastrectomy/esophagojejunostomy (TG) group (n=52), according to the methods of gastrectomy and reconstruction. The postoperative complications, nutritional status and prognosis of the two groups were compared. Results The incidence of reflux esophagitis was obviously higher in PG group than that in TG group (38.0% vs 19.2%, χ2=4.464, P=0.035). No significant differences were found between the two groups in the incidences of postoperative infection, bleeding and anastomotic leakage (χ2=0.063, P=1.000; χ2=0.001, P=0.978; χ2=0.311, P=0.577). There were no significant differences between PG and TG group in total plasma protein ［(65.26±4.10)g/L vs (65.33±3.75)g/L, t=-0.402，P=0.688］, albumin ［(39.76±2.17)g/L vs (39.59±2.04)g/L, t=1.778, P=0.076］, hemoglobin ［(107.33±11.10)g/L vs (108.09±11.17)g/L, t=-1.502, P=0.133］ and weight loss ［1.00~8.00 kg vs 0.50~8.20 kg, t=-1.622, P=0.105］ in one year postoperatively. All cases were followedup for 7 months to 10 years. No significant differences were found between PG and TG group in the incidences of anastomotic tumor recurrence (4.0% vs 5.8%, χ2=0.171, P=0.679), metastasis (24.0% vs 28.8%, χ2=0.308, P=0.579) and median survival time (53.6 months vs 49.8 months, χ2=2.564, P=0.109). Conclusion Compared with PG group, the incidence of postoperative reflux esophagitis is effectively reduced, and the incidences of malnutrition, tumor recurrence and metastasis and death are not increased in TG group. Hence, TG should be a safe and effective surgery strategy. References | Related Articles | Metrics

Clinical evaluation of oxaliplatin combined with S-1 or docetaxel for advanced gastric cancer Yang Shirong, Zhao Chengmao, Wang Rong, Mu Yuanzhong, Zhao Gang 2015, 42 (6):  426-429.  doi: 10.3760/cma.j.issn.1673-422X.2015.06.007 Abstract ( 565 )   PDF (964KB) ( 1189 )   Save Objective To evaluate the efficacy and safety of combination therapy of oxaliplatin and S1 vs oxaliplatin and docetaxel for advanced gastric cancer (AGC) patients. Methods From April 2011 to January 2013, 62 cases of AGC were collected in the Fifth People′s Hospital of Qinghai Province. All cases were randomly divided into group A (31 cases) and B (31 cases) by random number table. In group A, oxaliplatin plus S-1 was administered, and in group B, oxaliplatin plus docetaxel was applied. The response rate (RR), time of diseases controlled rate (DCR), progressionfree survival (PFS), overall survival (OS) and adverse reactions of the two groups were observed and compared. Results There were no statistically differences between group A and group B in RR (48.4% vs 54.8%), DCR (67.7% vs 77.4%), mPFS (5.4 months vs 6.2 months), mOS (9.0 months vs 9.8 months), and the statistical values were as follows: χ2=0.26, P=0.711; χ2 =0.73, P=0.393; χ2=0.51, P=0.473; χ2=0.03, P=0.829. The incidence of degrees Ⅰ-Ⅱ peripheral neuropathy (9.7% vs 22.6%), nausea and vomiting (12.9% vs 32.3%) in group A were significantly lower than those in group B (χ2=5.78, P=0.002; χ2=4.63, P=0.016). Conclusion Both the two chemotherapies are similar in therapeutic effect for patients with AGC. Oxaliplatin plus S-1 treatment may be better than oxaliplatin plus docetaxel in the tolerance of patients. References | Related Articles | Metrics

Chemoprevention and therapy of tea polyphenol of colorectal cancer in colorectal cancer rats and cells: a systematic review Liu Yuting, Qi Jian 2015, 42 (6):  430-435.  doi: 10.3760/cma.j.issn.1673-422X.2015.06.008 Abstract ( 350 )   PDF (2069KB) ( 1058 )   Save Objective To evaluate the chemoprevention and therapy of tea polyphenol of colorectal cancer in colon cancer rats and cells. Methods Such database as CBM, CNKI, VIP, Wanfang, PubMed, Medline, EMBase, Cochrane Library were searched for collecting the papers including using tea polyphenol as a therapy and chemoprevention of colorectal cancer in colorectal cancer rats and colorectal cells, from their establishment to June 1, 2014, and the references of those related papers were also searched by hand. After studying selection, assessment and data extraction were conducted by two reviewers. RevMan5.2 software was used for Meta-analyze. Results Seventeen studies were included. Three hundred and five rats and 5 colorectal cell lines were used to the research, they were divided into the study group (received the tea treatment) and the control group (not received the tea treatment). The results of metaanalyses showed that: ① Aberrant crypt foci (ACF): standardized mean difference SMD=-3.69(95%CI为-5.85～-1.54， Z=3.40, P=0.000 8), which indicated that tea polyphenol could reduce the number of ACF. ② The average number of tumors per rat: SMD=-0.83 (95%CI: -1.14～-0.51, Z=5.18, P=0.000 01), which indicated that tea polyphenol could reduce the average number of tumors per rat. ③ Cell cycle G1 phase: SMD=1.85(95%CI: 0.03～3.66, Z=1.99,P=0.05), which indicated that tea polyphenol could increase the cell in G1 phase. ④ Cell cycle S phase: SMD=-2.64(95%CI: -4.38～-0.90, Z=2.98, P=0.003), which indicated that tea polyphenol could decrease colon cancer cell in S phase. Conclusion Tea polyphenol has a positive effect on colon cancer cell and colon cancer rats. References | Related Articles | Metrics

Cytokeratin 14 and cancer Zhang Weiquan, Zhao Xiaogang 2015, 42 (6):  436-438.  doi: 10.3760/cma.j.issn.1673-422X.2015.06.009 Abstract ( 1327 )   PDF (713KB) ( 1789 )   Save Cytokeratin 14 (CK14) has a different degree of expression in NSCLC, breast cancer, cervical cancer, esophageal cancer and other tumors, except in the normal basal cells. CK14 is mainly expressed in the peripheral part of the tumor, which is rarely expressed in the nonaggressive part. Usually the higher malignant of the tumor has the more expression of CK14. Given all that, CK14 gene plays an important role in the tumor progression and metastasis in a variety of tumors, which can be considered as an biomarker being used in the diagnosis, treatment and prognosis evaluation. References | Related Articles | Metrics

Molecular mechanism of long non-coding RNAs in tumor drug resistance Lian Yifan, Wang Keming 2015, 42 (6):  439-441.  doi: 10.3760/cma.j.issn.1673-422X.2015.06.010 Abstract ( 318 )   PDF (716KB) ( 1711 )   Save Long non-coding RNAs (lncRNAs) are closely related to the tumorigenesis, proliferation, metastasis and clinical outcome, whihc play important roles in the process of drug resistance of many tumor cells. Recently, research indicates that many lncRNAs regulate drug resistance of tumor cells through a variety of signaling pathways both in vitro and in vivo. Furthermore, it is also found that after blocking the relevant targets can reverse this chemoresistance. References | Related Articles | Metrics

Trim family and tumor Yang Qingmei, Xu Zumin, Guan Chengnong 2015, 42 (6):  442-444.  doi: 10.3760/cma.j.issn.1673-422X.2015.06.011 Abstract ( 759 )   PDF (715KB) ( 1687 )   Save Studies show that some Trim family proteins are associated with tumorigenesis and cancer progression. Trim members are differently expressed in various cancers including lung cancer, hepatocellular carcinoma, colon cancer, stomach cancer and breast cancer. Trim proteins are found to be involved in tumor progess by modulating the expression of tumor associated genes via several signaling pathways such as p53 and NFκB pathway. Members of Trim family can be used as oncogenes or antioncogenes in the biological processes such as tumor cell proliferation, cell differentiation, cell apoptosis and metastasis. References | Related Articles | Metrics

Mechanism and prevention of the formation of hypercoagulable state in patients with malignant tumor Zhang Guangming, Wang Zheng, Zhang Xuewei, Geng Ping 2015, 42 (6):  445-447.  doi: 10.3760/cma.j.issn.1673-422X.2015.06.012 Abstract ( 1663 )   PDF (714KB) ( 2584 )   Save The majority of patients with malignant tumors have hypercoagulable state, which easily leads to thrombosis, and is closely related with recurrence of tumor metastasis. The formation mechanism of hypercoagulable state is related to tumor, tumor treatment, complications etc. The main diagnostic indicators are the platelet, cruor and fibrinolysis, Pselectin and lysosomal protein, blood rheology. Tumor patients with the high risk of thrombus should use low molecular weight heparin. Thromboembolism should be prevented in bedridden patients with tumor and tumor associated operation. Tumor patients with venous thromboembolism should be given thrombolytic treatment. Tumor patients with hypercoagulable state should be treated by anticoagulant therapy combined with chemotherapy. References | Related Articles | Metrics

Effect of tumor radiotherapy on the immune response Kong Yuehong, Ding Jiping, Tu Wenyong 2015, 42 (6):  448-451.  doi: 10.3760/cma.j.issn.1673-422X.2015.06.013 Abstract ( 517 )   PDF (721KB) ( 1401 )   Save Tumor radiation therapy (RT) can affect the immune system. Latest studies show that appropriate RT can activate the immune system through regulating tumor microenvironment, activating immune cells and releasing danger signals, and can produce bystander or abscopal effect. With the development of clinical biomarkers research and clinical trials about RT combined with immunotherapy, it is expected to change the traditional pattern of tumor treatment. References | Related Articles | Metrics

Targeted therapy for small cell lung cancer Wang Wenxian, Zhang Yiping 2015, 42 (6):  452-454.  doi: 10.3760/cma.j.issn.1673,422X.2015.06.014 Abstract ( 327 )   PDF (716KB) ( 1503 )   Save argeted agents for small cell lung cancer (SCLC) include inhibitors of angiogenesis, tyrosine kinase inhibitors and signal transduction pathway inhibitors. Bevacizumab, a class of antiangiogenic agent, tends to have no effects on patients. The tyrosine kinase inhibitor, for example sunitinib, may be used as a monotherapy. Signaling inhibitors including Amuvatinib and LDE225 are undergoing phaseⅠand Ⅱ trials. Primary data show that SCLC is not sensitive to targeted therapy, needing more selection, so further studies are requested. References | Related Articles | Metrics

Treatment of non-small cell lung cancer with brain metastasis Wang Xiaolei, Liu Deze, Liu Weiwei, Jia Lin, Wang Min 2015, 42 (6):  455-457.  doi: 10.3760/cma.j.issn.1673-422X.2015.06.015 Abstract ( 338 )   PDF (715KB) ( 1318 )   Save 30%-50% patients with nonsmall cell lung cancer (NSCLC) will occur cerebral metastasis in the course of their illnesses. NSCLC with brain metastases is one of the difficulties in cancer treatment. Treatment measures include surgery, radiotherapy, chemotherapy, biological targeted therapy and so on. The new prognostic scoring system is recommended to predict the prognosis of patients. Individualized treatment methods should be chosen according to prognostic score. References | Related Articles | Metrics

Acquired resistance mechanisms of EGFR-TKI in advanced non-small cell lung cancer Zheng Yue, Wei Suju 2015, 42 (6):  458-461.  doi: 10.3760/cma.j.issn.1673-422X.2015.06.016 Abstract ( 350 )   PDF (722KB) ( 1785 )   Save Since the development of molecular biology, the treatment of advanced non-small cell cancer is shifting from traditional chemotherapy into molecular targeted therapy with genotyping as a guide′s help. The most widely used is epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). With the application of EGFRTKIs, the resistances to EGFR inhibitors are paid more and more attention, in recent years. The main mechanisms of acquired resistances are as follows: secondary mutation of the EGFR gene, amplification of c-MET, Her2 and other target genes, histological transformation, activation of the bypass mechanisms, loss of p53, the relief of negative feedback loops, overlap of mechanisms, etc. References | Related Articles | Metrics

Advances of malignant pleural mesothelioma Wu Xinshu, Zhao Xiaogang, Wu Licun, Cong Bo 2015, 42 (6):  462-465.  doi: 10.3760/cma.j.issn.1673-422X.2015.06.017 Abstract ( 532 )   PDF (721KB) ( 1690 )   Save Malignant pleural mesothelioma (MPM) is a malignant cancer originated from pleural mesothelial cell. The diagnosis of MPM is based on biopsy of pleura and immunohistochemistry. The current treatment of MPM is multimodality therapy including surgery, radiotherapy, chemotherapy and immunotherapy. There are two major surgical procedures: extrapleural pneumonectomy and pleurectomy/decortication. The main of radiotherapy is threedimensional conformal radiotherapy. Cisplatinum combined with pemetrexed is the firstline chemotherapy for the patients with MPM. The principal targets for immunotherapy include regulatory T cells, cytotoxic T lymphocyte associated antigen 4 and PD 1. References | Related Articles | Metrics

Clinical applications of circulating tumor cells detection in gastric carcinoma Lu Xinyang, Cui Kai, Li Sheng 2015, 42 (6):  466-468.  doi: 10.3760/cma.j.issn.1673-422X.2015.06.018 Abstract ( 361 )   PDF (715KB) ( 1189 )   Save Circulating tumor cells (CTCs) are special kind of tumor cells in the peripheral blood of patient with tumor. Now CTCs detection has been used in the survival time prediction, postoperational recurrence detection, individualized treatment and other aspects in the patients with gastric cancer. As the research going, CTCs will provide new help for the comprehensive treatment of gastric cancer. References | Related Articles | Metrics

Research progress of Antrodia cinnomomea on the anti-hepatocarcinoma mechanism Chen Qingfa, Zhao Zongjie, Xie Haitao, Zhang Xiangyang, Wang Pengting 2015, 42 (6):  469-471.  doi: 10.3760/cma.j.issn.1673-422X.2015.06.019 Abstract ( 296 )   PDF (713KB) ( 1436 )   Save Extensive in vitro studies reveal that multiple intracellular targets of Antrodia cinnomomea affect cell growth, apoptosis, angiogenesis, invasion and metastasis. These intracellular targets include tumor suppressor gene, cell cycle regulatory protein, transcription factor, angiogenic and metastatic factors, and apoptotic and survival regulators. In addition, Antrodia cinnomomea has immunomodulatory propertie, which plays an anti-cancer effect indirectly by means of enhancing immunity. References | Related Articles | Metrics

Application of interim 18FFDG PET-CT in lymphoma Zhang Yuewei, Wang Xuejuan, Yang Zhi, Zhu Jun 2015, 42 (6):  472-474.  doi: 10.3760/cma.j.issn.1673-422X.2015.06.020 Abstract ( 495 )   PDF (776KB) ( 1253 )   Save Interim fluorine 18 fluorodeoxyglucose (18FFDG) positron emission tomography (PET) integrated with computed tomography (CT) provides both metabolic and morphologic information, which becomes one of the most sensitive tools to evaluate the efficacy of the therapy and predict the prognosis of patients with lymphoma. Meanwhile, it is the basis for guiding trial design and changing clinical practice. However, it is still a controversial issue in the ideal utilization of interim 18FFDG PET-CT imaging for the patients with lymphoma. References | Related Articles | Metrics

Research progress of HIV/AIDS related lymphoma Wang Di, Feng Yanling 2015, 42 (6):  475-477.  doi: 10.3760/cma.j.issn.1673-422X.2015.06.021 Abstract ( 381 )   PDF (716KB) ( 1084 )   Save HIV/AIDS related lymphoma (ARL) are a group of heterogeneity of neoplasms, and they have poor prognosis. The factors of pathogenesis elucidated in recent years include immune injury caused by HIV, EB virus infection and genetic changes. There are four pathological types of ARL, including diffuse large B cell lymphoma, Burkitt lymphoma, plasmablastic lymphoma and primary effusion lymphoma. Morphological characteristics, immunophenotype markers and clinical data should be combined to make diagnosis and differential diagnosis, which will facilitate timely treatment and improve prognosis. References | Related Articles | Metrics